Company recalls weight loss supplements

A South Florida company is voluntarily recalling weight loss supplements called "JaDera" and "Xiyouji Qingzhi."

Florida Dolphin Intertrade Corp. announced Friday that these products have been found to contain undeclared Sibutramine, which was a previously approved controlled substance for the treatment of obesity. It was removed from the U.S. market in October 2010 for safety reasons.

Florida Dolphin Intertrade says that products containing Sibutramine are known to substantially increase blood pressure and pulse rate in some patients and may present a significant risk for patients with a history of , , arrhythmias or stroke. These products may also interact in life threatening ways with other medications a consumer may be taking.

The supplements were distributed from May 2011 to May 2013.

Consumers with questions regarding this recall can contact 305-383-7600

not rated yet
add to favorites email to friend print save as pdf

Related Stories

FDA seizes illegal dietary supplements in Florida

Feb 14, 2013

(AP)—The Food and Drug Administration says U.S. marshals have seized illegal dietary supplements from a Florida company because some may contain a dangerous pharmaceutical ingredient.

Fla. compounding pharmacy recalls sterile drugs

Apr 21, 2013

A Florida-based compounding pharmacy is voluntarily recalling all lots of its sterile non-expired drug products sold nationwide over concerns the products are not sterile and may contain bacteria.

Farm Rich products recalled over E. coli fears

Mar 29, 2013

(AP)—Rich Products Corp. has announced a voluntary recall of its Farm Rich Mini Quesadillas and other Farm Rich products because of a possible contamination with E. coli bacteria.

Recommended for you

Boxed warnings are common in novel therapeutics

12 hours ago

(HealthDay)—Boxed warnings are common on recent drug approvals, and many occur years after approval, according to a research letter published online Aug. 15 in JAMA Internal Medicine.

AstraZeneca says DOJ closes probe into drug trial

13 hours ago

British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action.

Perampanel for epilepsy: Still no proof of added benefit

14 hours ago

The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive ("add-on") therapy for adults and children aged 12 years and older with epileptic fits (seizures). In a new early benefit assessment ...

User comments